journal article·2023-07-19

Bioprinted Multicomponent Hydrogel Co-culture Tumor-Immune Model for Assessing and Simulating Tumor-Infiltrated Lymphocyte Migration and Functional Activation

Salvador Flores-Torres, Nikolaos M. Dimitriou, Lucas Antonio Pardo, Jacqueline Kort-Mascort, Sanjima Pal, Omar Peza-Chavez, Hellen Kuasne, Julie Berube, Nicholas Bertos, Morag Park, Georgios D. Mitsis, Lorenzo Ferri, Veena Sangwan, Joseph M. Kinsella

ACS Applied Materials & Interfaces· Volume 15· Issue 28
Publisher page

Abstract

The immune response against a tumor is characterized by the interplay among components of the immune system and neoplastic cells. Here, we bioprinted a model with two distinct regions containing gastric cancer patient-derived organoids (PDOs) and tumor-infiltrated lymphocytes (TILs). The initial cellular distribution allows for the longitudinal study of TIL migratory patterns concurrently with multiplexed cytokine analysis. The chemical properties of the bioink were designed to present physical barriers that immune T-cells must breech during infiltration and migration toward a tumor with the use of an alginate, gelatin, and basal membrane mix. TIL activity, degranulation, and regulation of proteolytic activity reveal insights into the time-dependent biochemical dynamics. Regulation of the sFas and sFas-ligand present on PDOs and TILs, respectively, and the perforin and granzyme longitudinal secretion confirms TIL activation when encountering PDO formations. TIL migratory profiles were used to create a deterministic reaction-advection diffusion model. The simulation provides insights that decouple passive from active cell migration mechanisms. The mechanisms used by TILs and other adoptive cell therapeutics as they infiltrate the tumor barrier are poorly understood. This study presents a pre-screening strategy for immune cells where motility and activation across ECM environments are crucial indicators of cellular fitness.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: 3D Printing in Biomedical Research · Cancer Cells and Metastasis · Cellular Mechanics and Interactions

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Bioengineering, McGill University, Montreal H3A 0G4, Quebec, Canada

Department of Surgery, McGill University, Montreal H3A 0G4, Quebec, Canada

Rosalind and Morris Goodman Cancer Institute, McGill University, Montreal H3A 0G4, Quebec, Canada

Research Institute of the McGill University Health Centre (RI-MUHC), Montreal H3G 2M1, Quebec, Canada

Department of Biochemistry, McGill University, Montreal H3A 0G4, Quebec, Canada

Department of Medicine, McGill University, Montreal H3A 0G4, Quebec, Canada

Department of Oncology, McGill University, Montreal H3A 0G4, Quebec, Canada

Department of Pathology, McGill University, Montreal H3A 0G4, Quebec, Canada

Funding

Faculty of Engineering, McGill University · Fonds de Recherche du Qu??bec - Nature et Technologies · Government of Canada · Cancer Research Society

References (83)

Show source-provided references
1. 10.1016/j.jaci.2009.12.98010.1016/j.jaci.2009.12.980 ↗
2. 10.1101/gad.314617.11810.1101/gad.314617.118 ↗
3. 10.1016/j.immuni.2013.07.01210.1016/j.immuni.2013.07.012 ↗
4. 10.1158/1078-0432.ccr-14-186010.1158/1078-0432.ccr-14-1860 ↗
5. 10.1016/j.trecan.2017.09.00610.1016/j.trecan.2017.09.006 ↗
6. 10.1038/s41591-018-0014-x10.1038/s41591-018-0014-x ↗
7. 10.1016/j.eclinm.2021.10113410.1016/j.eclinm.2021.101134 ↗
8. 10.1186/s13058-015-0632-x10.1186/s13058-015-0632-x ↗
9. 10.1038/onc.2009.41610.1038/onc.2009.416 ↗
10. 10.1158/1424-9634.Dcl-3.9.110.1158/1424-9634.Dcl-3.9.1 ↗
11. 10.1007/s10555-011-9270-710.1007/s10555-011-9270-7 ↗
12. 10.3389/fimmu.2019.0016810.3389/fimmu.2019.00168 ↗
13. 10.7150/thno.5839010.7150/thno.58390 ↗
14. 10.1111/j.1365-2567.2007.02587.x10.1111/j.1365-2567.2007.02587.x ↗
15. 10.1038/s41417-021-00303-x10.1038/s41417-021-00303-x ↗
16. 10.1158/0008-5472.Can-12-202710.1158/0008-5472.Can-12-2027 ↗
17. 10.1186/s40425-019-0556-610.1186/s40425-019-0556-6 ↗
18. 10.1038/s41571-022-00721-210.1038/s41571-022-00721-2 ↗
19. 10.1002/0471142735.im1521s8110.1002/0471142735.im1521s81 ↗
20. 10.1002/mc.2319510.1002/mc.23195 ↗
21. 10.1021/acsabm.0c0147210.1021/acsabm.0c01472 ↗
22. 10.1002/adfm.20220396610.1002/adfm.202203966 ↗
23. 10.1088/1758-5090/ac925a10.1088/1758-5090/ac925a ↗
24. 10.1002/adma.20150172910.1002/adma.201501729 ↗
25. 10.1002/adma.20180659010.1002/adma.201806590 ↗
26. 10.1016/j.bprint.2022.e0023110.1016/j.bprint.2022.e00231 ↗
27. 10.1088/1758-5090/abdb8710.1088/1758-5090/abdb87 ↗
28. 10.3390/microarrays402013310.3390/microarrays4020133 ↗
29. 10.1016/j.cellimm.2008.08.00710.1016/j.cellimm.2008.08.007 ↗
30. 10.1038/s41467-021-25282-310.1038/s41467-021-25282-3 ↗
31. 10.1038/nature0793510.1038/nature07935 ↗
32. Murray J. D. · 2001 · 3
33. Murray J. D. · 200210.1007/b98868 ↗
34. 10.1080/1027366010883306710.1080/10273660108833067 ↗
35. 10.1093/imammb/21.1.110.1093/imammb/21.1.1 ↗
36. Lee H. J. · 200310.1201/9780203010518 ↗
37. Bezanson J. · arXiv preprint arXiv:1209.5145 · 2012
38. 10.5334/jors.15110.5334/jors.151 ↗
39. 10.1109/TSMCC.2004.84190610.1109/TSMCC.2004.841906 ↗
40. Johnson, S. G. (2014).10.52439/JKQT7126 ↗
41. 10.1162/evco.1996.4.4.40510.1162/evco.1996.4.4.405 ↗
42. 10.1093/comjnl/7.4.30810.1093/comjnl/7.4.308 ↗
43. 10.1215/s115285170300014010.1215/s1152851703000140 ↗
44. 10.1038/s41577-020-0306-510.1038/s41577-020-0306-5 ↗
45. 10.1016/s0140-6736(20)32334-510.1016/s0140-6736(20)32334-5 ↗
46. 10.1038/s41422-022-00721-y10.1038/s41422-022-00721-y ↗
47. 10.1039/c3ra23341c10.1039/c3ra23341c ↗
48. 10.1088/1758-5090/ab3a5c10.1088/1758-5090/ab3a5c ↗
49. 10.1007/s10856-016-5763-910.1007/s10856-016-5763-9 ↗
50. 10.1038/nrc169510.1038/nrc1695 ↗
51. 10.1002/pmic.20090075810.1002/pmic.200900758 ↗
52. 10.1016/j.semcancer.2005.05.00410.1016/j.semcancer.2005.05.004 ↗
53. 10.1038/nm94210.1038/nm942 ↗
54. 10.7554/eLife.5655410.7554/eLife.56554 ↗
55. 10.1172/jci11862510.1172/jci118625 ↗
56. 10.1016/j.immuni.2014.11.01210.1016/j.immuni.2014.11.012 ↗
57. 10.1038/nm0198-03110.1038/nm0198-031 ↗
58. 10.1002/1521-4141(200003)30:3<725::Aid-immu725>3.0.Co;2-d10.1002/1521-4141(200003)30:3<725::Aid-immu725>3.0.Co;2-d ↗
59. 10.1007/s00262005050510.1007/s002620050505 ↗
60. 10.1084/jem.184.3.107510.1084/jem.184.3.1075 ↗
61. 10.1034/j.1600-065X.2003.00051.x10.1034/j.1600-065X.2003.00051.x ↗
62. 10.1016/j.immuni.2009.01.00110.1016/j.immuni.2009.01.001 ↗
63. 10.1182/blood.V96.1.195.013k51_195_20210.1182/blood.V96.1.195.013k51_195_202 ↗
64. 10.1126/science.274.5291.136310.1126/science.274.5291.1363 ↗
65. Volpedo, G.; Pacheco-Fernández, T.; de Carvalho Clímaco, M.; Satoskar, A. R. Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives; Morales-Montor, J.; Segovia-Mendoza, M., Eds. Academic Press: 2021; Vol. 2, 47–68.10.1016/B978-0-12-822028-3.00013-3 ↗
66. 10.1038/nm.354110.1038/nm.3541 ↗
67. 10.1038/s41467-018-03347-010.1038/s41467-018-03347-0 ↗
68. 10.1016/j.ceb.2014.05.00310.1016/j.ceb.2014.05.003 ↗
69. 10.1371/journal.pcbi.100276310.1371/journal.pcbi.1002763 ↗
70. 10.1186/s13046-022-02484-110.1186/s13046-022-02484-1 ↗
71. 10.3389/fimmu.2021.65636410.3389/fimmu.2021.656364 ↗
72. 10.1172/JCI4581710.1172/JCI45817 ↗
73. 10.1158/1078-0432.Ccr-13-297210.1158/1078-0432.Ccr-13-2972 ↗
74. Drake, C. G.; Jaffee, E.; Pardoll, D. M. Advances in Immunology; Academic Press: 2006; Vol. 90, 51–81.10.1016/S0065-2776(06)90002-9 ↗
75. 10.1038/s41571-018-0007-110.1038/s41571-018-0007-1 ↗
76. 10.1038/cddis.2015.16210.1038/cddis.2015.162 ↗
77. 10.1016/j.ejphar.2020.17309010.1016/j.ejphar.2020.173090 ↗
78. 10.1007/s10555-010-9223-610.1007/s10555-010-9223-6 ↗
79. 10.1084/jem.2020085110.1084/jem.20200851 ↗
80. 10.1093/carcin/bgs12310.1093/carcin/bgs123 ↗
81. 10.1126/science.aaz086810.1126/science.aaz0868 ↗
82. 10.1038/s41416-021-01353-610.1038/s41416-021-01353-6 ↗
83. 10.1038/s41573-019-0051-210.1038/s41573-019-0051-2 ↗